GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oculis Holding AG (NAS:OCS) » Definitions » Interest Income

Oculis Holding AG (Oculis Holding AG) Interest Income : $2.23 Mil (TTM As of Mar. 2024)


View and export this data going back to 2023. Start your Free Trial

What is Oculis Holding AG Interest Income?

Interest Income is the interest earned on cash temporarily held in savings accounts, certificates of deposits, or other investments. Oculis Holding AG's interest income for the three months ended in Mar. 2024 was $0.65 Mil. Its interest income for the trailing twelve months (TTM) ended in Mar. 2024 was $2.23 Mil.


Oculis Holding AG Interest Income Historical Data

The historical data trend for Oculis Holding AG's Interest Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Oculis Holding AG Interest Income Chart

Oculis Holding AG Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Interest Income
0.01 0.02 0.14 1.65

Oculis Holding AG Quarterly Data
Dec20 Jun21 Sep21 Dec21 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Interest Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.04 0.24 0.58 0.76 0.65

Oculis Holding AG Interest Income Calculation

Interest Income is the interest earned on cash temporarily held in savings accounts, certificates of deposits, or other investments.

Interest Income for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $2.23 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Oculis Holding AG (Oculis Holding AG) Business Description

Traded in Other Exchanges
Address
Bahnhofstrasse 7, Zug, CHE, 6300
Oculis Holding AG is a global biopharmaceutical company purposefully driven to save sight and improve eye care. It includes OCS-01, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED); and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis.